Link: Mastereksamen: Henrik Tse Zhiong Hellesøy
Thank you for all the visitors, parents and friends who joined us.
For more information, follow this link
Forskningsmiljøet ved Radiumhospitalet har utviklet en ny, persontilpasset kreftvaksine for pasienter med en sjelden og alvorlig kreftform: pseudomyxoma peritonei (PMP) – kreft i blindtarmen med spredning til bukhinnen.
Read more here:Ny kreftvaksine utviklet på Radiumhospitalet – Pseudovaxstudien startet inklusjon i november 2025 - Oslo universitetssykehus HF
Kjersti Flatmark og Else Marit Inderberg er begge prosjektledere for Pseudovax-prosjektet.
Foto: Per Marius Didriksen, OUS
“Macrophage Reprogramming for Cancer Treatment”
11th of March 2026 at 9:30
Institute for Cancer Research, Seminar room 1, K-building
PROGRAM (program with additional speakers will be released by August 15, 2025)
Welcome by Moderators & Co-Chairs
Else Marit Inderberg, PhD, Unit Leader, Translational Research Unit, Section for Cell Therapy, Department of Oncology, Oslo University Hospital, Oslo, Norway
&
Tuva Holt Hereng, PhD, Senior Manager R&D Cell Therapy, Oslo, Norway
Speaker
Development of CAR-Treg therapies to modulate immune responses in transplantation and autoimmunity
Nathalie Belmonte, PhD, Senior VP Research and Technical Development, Quell Therapeutics
Solving CAR-T Manufacturing and QC Challenges with Structured Support and Strategic Solutions
Anna Pasetto, PhD, Associate Professor, Director of Center for Advanced Cell Therapy (ACT), Oslo University Hospital, Norway
Automated manufacturing of CAR effector cells: From viral to non-viral gene transfer
Ulrike Kohl, MD, PhD, Institute Director / University Professor, Institute of Clinical Immunology, Medical Faculty, University of Leipzig and Fraunhofer Institute for Cell Therapy and Immunology, Germany.
Maximizing the Innate Power of NK cells in cancer therapy
Ebba Sohlberg, PhD, Researcher and Project Manager at the Center for Infectious Medicine, Karolinska Institutet, Sweden
Additional speakers will be confirmed and updated here.
NOTE about a workshop the next day:
On October 9, 2025, 9am-5pm at OCC Innovation Park: You are invited to register your interest to join a specialized workshop conducted by Thermo Fisher Scientific. Please register your interest with corinna.pohl@thermofisher.com, who will contact you early Q3 2025 about the program.
We are happy to annunce that Christopher Forcaods who has been at the unit for 4 years will noon defend his thesis to obtain the degree of Philosophiae Doctor (PhD) deliver by the Medical Faculty of the University of Oslo.
(The hero in action 2 years ago)
You can either come to this address: Auditorium Nye RAD L1 (U1), Bygg L, Radiumhospitalet, Ullernchausseen 70
Or follow him online:
10:15 AM Trial Lecture: “Ideas and solutions for in vivo generation of chimeric antigen receptor T cells”
1:15 PM Public Defense: “Development of novel Chimeric Antigen Receptors against alternative targets”
More information can be found here
Congratulations to Dr. Christopher Forcados:
(picture S. Joaquina)
Sandy Joaquina will defend her thesis on the 26th of May:
The morning session (10:15) will be: "Epigenetic regulation of T-cell exhaustion"
and the defense (13:15):“Novel strategies for Chimeric Antigen Receptor therapies”
(Sandy at work, photo SW)
On the 27th, together with barnekreftforeningen and the Norwegian society for Immunology, we will organize a symposium with our prestigious guests.
27th of May 2025
Institute for Cancer Research, large Auditorium, K-building
Coffee at 9:15, starts at 9:30
